A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2001
11/22/2001	US20010044454 Thrombin receptor antagonists
11/22/2001	US20010044451 Tyrosine kinase inhibitors
11/22/2001	US20010044450 5-HT3 receptor antagonists such as alosetron to treat nonconstipated female irritable bowel syndrome
11/22/2001	US20010044444 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss
11/22/2001	US20010044442 Dimethoxy quinazolines for treating diabetes
11/22/2001	US20010044441 And female sexual dysfunction, premature labour or dysmenorrhea
11/22/2001	US20010044436 Bicyclic inhibitors of glycogen synthase kinase 3
11/22/2001	US20010044434 Treating timidity and enhancing libido in postmenopausal women, or treating male sexual dysfunction by administering to a patient in need thereof an effective amount of an estrogen agonist/antagonist
11/22/2001	US20010044421 Antimutagenic compositions for treatment and prevention of photodamage to skin
11/22/2001	US20010044420 Treatment of mammalian cancer
11/22/2001	US20010044419 Administering to skin a composition containing deoxyribonucleosides in concentrations sufficient to enhance DNA repair or reduce mutation frequency in a vehicle capable of delivering deoxyribonucleosides to skin cells
11/22/2001	US20010044411 Pain relieving and antiinflammatory drug, nutraceutical, and base, where one of drug or nutraceutical treats an ailment or symptom of an immune response, such as to a virus, microoganism, atmospheric pollutant or allergen
11/22/2001	US20010044410 Pain relieving and antiinflammatory drug, nutraceutical, and base, where one of drug or nutraceutical treats an ailment or symptom of an immune response, such as to a virus, microoganism, atmospheric pollutant or allergen
11/22/2001	US20010044148 EBV-infected stomach cancer cell line
11/22/2001	US20010044144 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
11/22/2001	US20010044120 Useful for the prevention or treatment of peptic ulcers in humans or mammals.
11/22/2001	US20010043959 Treating acid reflux disease or symptoms with a pharmaceutical such as cimetidine, famotidine, nizatidine, or ranitidine, and a nutraceutical such as ginger, licorice, or aloe vera extracts, and carrier
11/22/2001	US20010043956 Hangover cure
11/22/2001	US20010043933 Exposing bacteria culture to stress, separating the medium and stress response product from the bacteria, and filtering the separated product to form a filtrate, administering the filtrate to an animal; vaccine adjuvants, treat endotoxemia
11/22/2001	US20010043926 Pharmaceutical formulation
11/22/2001	CA2410067A1 Combination chemotherapy
11/22/2001	CA2409652A1 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
11/22/2001	CA2409445A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/22/2001	CA2409437A1 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	CA2409355A1 Neuroprotective and anti-proliferative compounds
11/22/2001	CA2409148A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
11/22/2001	CA2409141A1 Method for preventing allograft rejection
11/22/2001	CA2409108A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
11/22/2001	CA2409077A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
11/22/2001	CA2408842A1 Method for treating retinal degeneration with purinergic receptor agonists
11/22/2001	CA2408756A1 Immune potentiating compositions
11/22/2001	CA2408729A1 Delivery systems for treatment of vascular disease
11/22/2001	CA2408719A1 Antiproliferative drug and delivery device
11/22/2001	CA2408691A1 Compositions and methods for achieving immune suppression
11/22/2001	CA2408617A1 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
11/22/2001	CA2408608A1 Antiinflammatory drug and delivery device
11/22/2001	CA2408606A1 Drug combinations useful for prevention of restenosis
11/22/2001	CA2408530A1 Novel deoxynucleoside kinase enzyme variants
11/22/2001	CA2408374A1 Mutation in the .beta.2 nicotinic acetylcholine receptor subunit associated with nocturnal frontal lobe epilepsy
11/22/2001	CA2408373A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
11/22/2001	CA2408163A1 Methods for treatment of inflammatory diseases
11/22/2001	CA2407469A1 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	CA2407099A1 Aralkyl ester soft drugs
11/21/2001	EP1156334A2 Method for screening a substance having promoting activity on hair growth
11/21/2001	EP1156332A2 Assay methods for cyclin dependent kinases
11/21/2001	EP1156110A2 G-protein coupled receptor (HFGAN72Y)
11/21/2001	EP1155691A2 Anti-angiogenic compositions and methods of use
11/21/2001	EP1155690A2 Anti-angiogenic compositions and method of use
11/21/2001	EP1155689A2 Anti-angiogenic compositions and methods of use
11/21/2001	EP1155037A1 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists therof, and their therapeutic uses
11/21/2001	EP1155030A1 Novel component of von hippel-lindau tumor suppressor complex and scf ubiquitin ligase
11/21/2001	EP1154988A1 Mevinolin derivatives
11/21/2001	EP1154819A2 Treatment regimen for hormone-sensitive cancers
11/21/2001	EP1154804A1 Bioadhesive antibacterial wound healing composition
11/21/2001	EP1154794A1 Agent containing an additional local anaesthetic for the treatment of symptoms of parkinson's disease
11/21/2001	EP1154788A1 Inhibitors of separin, method for identifying them and uses
11/21/2001	EP1154785A2 Inhibitors for use in hemostasis and immune function
11/21/2001	EP1154779A2 Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started
11/21/2001	EP1154773A2 Use of antagonists of pg-e for the treatment of neuropathic pain
11/21/2001	EP1154771A1 Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
11/21/2001	EP1154734A1 Injectable collagen-based system for delivery of cells or therapeutic agents
11/21/2001	EP1154691A1 Targeted transscleral controlled release drug delivery to the retina and choroid
11/21/2001	EP0998292B1 Method for inhibiting bone resorption
11/21/2001	EP0831910B1 Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
11/21/2001	EP0765168B1 Combination of a procoagulant and a cytokine or an inducer of cytokine production for the treatment of tumors
11/21/2001	CN1323396A Endogenous constitutively activated G protein-coupled orphan receptors
11/21/2001	CN1323346A TPL-2/COT kinase and methods of use
11/21/2001	CN1323309A Phenyl yanthine derivatives
11/21/2001	CN1323308A New compounds
11/21/2001	CN1323302A N-cimidazolylalkyl) substituted cyclic amines as histamine-H3 agonists or antagonists
11/21/2001	CN1323298A New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists
11/21/2001	CN1323294A Cyclic ester or amide derivatives
11/21/2001	CN1323223A Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
11/21/2001	CN1323218A The use of glial cell line-derived neurotrophic factor family-related compounds for regulating spermatogenesis and for preparing male contraceptives
11/21/2001	CN1323213A Blood-brain barrier therapeutics
11/21/2001	CN1323212A A method of modulating ion channel functional activity
11/21/2001	CN1323211A New pharmaceutical uses for NOS inhibitors
11/21/2001	CN1323209A Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
11/21/2001	CN1323200A New oral formulation for 5-HT4 agonists or antagonists
11/21/2001	CN1323199A Liposome-entrapped topoisomerase inhibitors
11/21/2001	CN1323186A Two chamber cartridge for atomizers
11/21/2001	CN1322526A Compound for treating female sexual dysfunction
11/21/2001	CN1074933C Anti-stress, anti-impairment and anti-aging medicine and process for manufacturing thereof
11/20/2001	US6320037 IBD-associated microbial nucleic acid molecules
11/20/2001	US6320036 GbpA
11/20/2001	US6319955 And a non-mek1 inhibitor anti-stroke agent selected from the group consisting of n-methyl-d-aspartate (nmda) receptor antagonists, immunosuppressants and caspase inhibitors
11/20/2001	US6319954 Administered to treat one or more withdrawal symptoms resulting from an addictive psychostimulant.
11/20/2001	US6319953 Provides preclinical screens for anxiolytic and antidepressant activity of nk-1 receptor antagonists.
11/20/2001	US6319942 May be applied directly to scar tissue, or embedded in linaments held against the scars.
11/20/2001	US6319931 Use of a compound with affinity for the mitochondrial benzodiazepine receptor in cancer therapy
11/20/2001	US6319912 Administering daily dosage units of a progestational agent equal in progestational activity of levonogestrel, second phase of dosage of antiprogesin comprising benzisothiazoline derivative and third phase of placebo for contraception
11/20/2001	US6319906 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
11/20/2001	US6319904 Useful as an antiulcer agent, showing potent anti-helicobacter pylori activity
11/20/2001	US6319894 Complexes and combinations of fetuin with therapeutic agents
11/20/2001	US6319688 Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
11/20/2001	US6319682 Methods and systems for assessing biological materials using optical and spectroscopic detection techniques
11/20/2001	US6319513 Oral liquid mucoadhesive compounds
11/20/2001	US6319510 Pad to be installed on gum comprising nonporous layer, adjacent layer retaining medication capable of being liquefied by saliva, semipermeable layer covering second layer and sealed to first layer to form pocket enclosing second layer
11/20/2001	US6319192 Method for the treatment of fertility disorders
11/20/2001	CA2297163C Gaba analogs to prevent and treat gastrointestinal damage

1 ... 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 ... 1151